NEW YORK (GenomeWeb) – Qiagen today announced a collaborative deal with AstraZeneca to develop a liquid biopsy-based companion diagnostic for the drugmaker's targeted non-small cell lung cancer therapy Iressa (gefitinib).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.